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Abstract
Background: Pertussis is believed to be widely underreported and under-recognized, particularly among adults.
The aim of this study was to estimate the incidence of private practitioner-attended cough illness that could be
attributed to Bordetella pertussis in adults aged ≥50 years in the US.
Methods: Multiple linear regressions were employed to estimate the overall incidence of pertussis. Data were
extracted from IMS’ private practice database of longitudinal, patient-level claims and IMS’ commercial laboratory
database during 4/1/2006–12/31/2010. Patients were ≥50 years old and had ≥1 ICD-9-CM claim for cough illness
relating to pertussis, cough, or acute bronchitis. Pertussis positive laboratory tests, seasonal and secular variables
were used for estimating the B. pertussis attributable fraction of cough illness.
Results: During the study period, there were 20.7 million cases of cough illness among people aged 50–64 and
27.5 million cases among those ≥65; of which the model attributed 2.5 and 1.7 %, respectively, to B. pertussis. The
estimated incidences of cough illness attributed to B. pertussis during the study period were on average 202 and
257/100,000 among people aged 50–64 and ≥65 years, respectively, and increased over the years in both age
groups. Depending on the year, estimated pertussis incidences were 42 to 105 times higher than medically
attended ones in the same database.
Conclusions: These findings indicate that the B. pertussis disease incidence in adults aged ≥50 years is significantly
higher than generally estimated. Additional research regarding pertussis reporting and diagnosis in the adult
populations is needed to validate these findings.
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Background
Pertussis (whooping cough), caused by Bordetella pertussis
(B. pertussis), is a highly contagious respiratory tract illness
[1]. Although introduction of universal infant pertussis
immunization led to an initial reduction in incidence [2, 3],
this has recently increased again worldwide, potentially due
to factors such as waning immunity, better diagnostic test-
ing, active surveillance, altered vaccine characteristics, and
increased awareness [2, 4]. Among adults, pertussis gener-
ally results in a prolonged cough, and can cause pharyngeal
discomfort, influenza-like symptoms, hoarseness, sinus
pain, and may lead to complications such as urinary incon-
tinence, rib fracture, pneumothorax, inguinal hernia, and
otitis media [5]. In addition, adults can pass infection to
young infants [6, 7], in whom severe complications and
death can occur [6, 8].
In the United States, the Advisory Committee on
Immunization Practices (ACIP) has consistently advised
that vaccination offers the best protection against pertussis
[9]. In 2006 ACIP recommended the administration of a
reduced antigen content tetanus toxoid, diphtheria toxoid,
and acellular pertussis (Tdap) vaccine to all adolescents
and adults 19 through 64 years of age [3]. In February
2012, the ACIP extended the Tdap recommendation to
adults aged 65 years and older [10].* Correspondence: cristina.masseria@pfizer.com1Global Health & Value, Pfizer Inc., 235 E 42nd street, New York, NY 10017,
USA
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There is a paucity of information on the true incidence
of pertussis, as many cases are not reported and/or la-
boratory confirmed [11–14]. Underreporting and under
diagnosis is considered to be a major issue, particularly
among adults. In addition, adults tend to seek medical
care much later in the course of the illness, when con-
firmation of the disease by laboratory testing is less
sensitive. Distinguishing pertussis from other respiratory
illnesses is challenging and clinicians are not often aware
of pertussis among adults. Confirmation of disease via
culture and polymerase chain reaction (PCR) also poses
challenges among adults [11–14].
A better understanding of pertussis incidence in
mature adults (those >50 years) is necessary to develop
effective clinical approaches and public health programs
to curb its spread. In absence of direct estimates of
disease incidence, inferential statistical methods can be
used to estimate the true disease incidence of pertussis
infections. This methodology has been used extensively to
estimate the incidence of other underreported diseases
that are rarely confirmed by laboratory testing, such as
influenza [15–17]. The covariation of etiology-specific
cough illness and laboratory-confirmed B. pertussis infec-
tions throughout the length of the time series is used for
attributing a proportion of cough illness to pertussis infec-
tions, after correcting for seasonal and secular trends. The
objective of this study was to estimate the incidence of pri-
vate practitioner-attended cough illness that could be statis-
tically attributed to B. pertussis in adults aged ≥50 years in
the US. The data presented here was part of a larger study.
Phase I results have recently been published [18] and will
be used for comparing the estimated pertussis incidence




Data were extracted from IMS’ private practice database
(CMS-1500) of longitudinal, patient-level claims (April
2006 to December 2010). This private practitioner
claims database contains claims completed for insured
patients seen by private practitioners across the 50 states
of America. This database constitutes the largest on-
going tracking program of outpatient office visit data in
the US, with approximately 1 billion entries and over 80
million claims per year submitted by more than 870,000
physicians per month. Between 2006 and 2010 over 100
million unique patients aged 50 and over were observed
in the database.
Data regarding B. pertussis laboratory tests were extracted
from IMS’ commercial laboratory partner (April 2006 to
December 2010), which covered approximately 40 % of
US-performed testing. Laboratory tests used for B pertussis
were: Polymerase Chain Reaction; PCP antigen detection,
culture or singe sera IgA, IgG, and or IgM titers.
Data were de-identified by assigning each patient with
a longitudinal identifier. The databases are third-party
certified as being compliant with the Health Insurance
Portability and Accountability Act.
Sample
Patients were included if they were ≥50 years old, with a
date of service between 4/1/2006 and 12/31/2010 and
with a cough illness (Table 1). More information on the
demographic and baseline characteristics of patients in-
cluded in this study is reported in the Phase I study [18].
Pertussis was defined using the following International
Classification of Diseases, Ninth Revision (ICD-9) diag-
nosis codes: pertussis/whooping cough (033.0 [due to B.
pertussis], 033.9 [unspecified organism], 484.3 [pneumo-
nia in whooping cough]). The definition of cough illness
included the above pertussis-related ICD9 codes, and
‘pertussis like conditions’ [cough (786.2), or acute bron-
chitis (466.0)]. Cough and acute bronchitis (categorized
as part of a larger lower-respiratory tract infection
group) were chosen because they were the conditions
(based on ICD9 codes) most frequently diagnosed in the
three months preceding a pertussis diagnosis among
patients aged 50 and older in the IMS database [18]. The
majority of patients had a ‘pertussis-like condition’ diag-
nosed in the three months preceding pertussis diagnosis
and approximately 90 % of these were acute respiratory
conditions, and 43 % had specifically either a cough and/
or acute bronchitis diagnosis.
Only patients with positive laboratory tests were in-
cluded for model estimates.
Data were stratified by age of the patients into 2
groups (50–64, ≥ 65) and aggregated by calendar month.
Regulatory and ethical considerations
The study was conducted in accordance with the applic-
able regulatory requirements, the International Confer-
ence on Harmonization, Guideline for Good Clinical
Practice, subject privacy requirements, and the guiding
principles of the Declaration of Helsinki. Data transmit-
ted to the study investigators was clean of all personally
identifiable information. No data that could link back to
individual patients were included. All data were aggre-
gated prior to sharing with GSK.
Analysis – estimation of the catchment population/
denominator
Incidence rates per 100,000 persons were calculated by
dividing the projected number of cough illness and
whooping cough cases attributable to B. pertussis by the
US Census populations [19] according to age group and
year and multiplying the product by 100,000. IMS’ private
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practice database does not capture data from every US
private practice, therefore to ensure that the data repre-
sent appropriately the US population, the data were pro-
jected up to Primary Census Statistical Areas (PCSAs).
The total of office-based American Medical Association
practitioners [20] was divided by the corresponding num-
ber of practitioners in the IMS sample. This was done
using IMS’ medical data projection weights [18, 21], esti-
mated by month and physician specialty strata.
Only private practitioners with relevant longitudinal
submission of claims were included in the sample to en-
sure accuracy of the weighted incidence calculations.
They represented 9 % (in 2006) to 17 % (in 2010) of all
General Practice, Internal Medicine or Geriatrics practi-
tioners in the US [18].
Analysis – modeling
The model selected for estimating the incidence of
cough illness attributable to pertussis has previously
been used in an international study of influenza and was
chosen because it allows to capture underreporting [15].
Similar models have been used in several therapeutic
areas (rotavirus, respiratory syncytial virus, and influ-
enza) [17, 22, 23].
The multiple linear regression model applied to the
data to determine the incidence of cough illness that
could be attributed to B. pertussis is described below:
Cough illness rate ¼ β0 þ β1B: pertussis
þ β2sine 2tπ=12ð Þ
þ β3cosine 2tπ=12ð Þ
þ β4t þ β5 ttð Þ þ e
The dependent variable, cough illness rate, was equal
to the cough illness incidence. The term β0 was the con-
stant term. B. pertussis represented the laboratory tests
positive for B. pertussis for each month in the time
period of interest. β1 was the regression coefficient used
for estimating the number of cough events attributable
to B. pertussis. The next two independent variables in
the equation and their corresponding coefficients (β2
and β3) were included to account for seasonal changes
in the dependent variable [24–26]. The last two inde-
pendent variables in the equation and their associated
coefficients (β4 and β5) accounted for linear and non-
linear trends in the dependent variable that were not as-
sociated with the cough illness/B. pertussis positive la-
boratory test signal in the time series. The variable t
represented the month in the time series analysis and e
represented the error term. Independent variables with
non-statistically significant (i.e. p >0.1) coefficients were
excluded from the model (the only case was Tdap vac-
cination). The regressions were run using Stata SE 9 and
SAS 9.2.
Model fit and attribution of cough to B. pertussis
The monthly attribution of the cough illness rate to B.
pertussis was generated by computing the products of
the regression coefficient associated with B. pertussis (i.e.
β1) and the monthly count of laboratory tests positive
for B. pertussis. The annual attribution was obtained by
summing the monthly totals within each year. Then, the
percentage attribution was calculated using the predicted
and observed sums of cough illness in each year as the
denominators.
The model-predicted and observed monthly cough ill-
ness rates to B. pertussis were compared for both age
groups, with a satisfactory visual fit of the model.
Study objective
The objective was to estimate the incidence of private
practitioner-attended cough illness that could be attrib-
uted to B. pertussis in adults aged 50–64 and ≥65 years
old in the US.
Table 1 PCSA population: projected rates of cough illness/ ICD-9 pertussis and actual laboratory tests
Year PCSA population Cough illnessa ICD-9
pertussisb
Incidence of medically reported
pertussis per 100,000c
Lab tests total (% positive)
50-64 y ≥65 y 50-64 y ≥65 y 50-64 y ≥65 y 50-64 y ≥65 y 50-64 ≥65 y
2006d 47,692,685 34,408,408 2,420,259 3,410,356 1580 1064 3.0 2.9 2694 (36.2 %) 1415 (29.1 %)
2007 49,339,902 34,949,825 3,631,552 4,954,117 1332 1020 2.5 2.7 4121 (33.3 %) 2007 (27.9 %)
2008 50,995,966 35,448,456 4,422,844 5,981,570 1176 1285 2.1 3.3 4382 (37.6 %) 2103 (29.7 %)
2009 52,378,740 36,335,561 4,980,846 6,388,537 1957 1209 3.5 3.1 4832 (38.7 %) 2631 (35.4 %)
2010 53,604,318 37,372,356 5,256,210 6,763,574 2719 1790 4.6 4.4 6621 (38.2 %) 4141 (36.2 %)
Total 254,011,611 178,514,606 20,711,712 27,498,154 8764 6368 3.15 3.27 22,650 (37.1 %) 12,297 (32.8 %)
PCSA Primary Census Statistical Area
aICD-9 codes: 033.0 (pertussis/whooping cough due to B. pertussis), 033.9 (pertussis/whooping cough due to unspecified organism), 484.3 (pneumonia in whooping
cough), 786.2 (cough), 466.0 (acute bronchitis)
bICD-9 codes: 033.0, 033.9, 484.3
cFor more information on the incidence calculation and the descriptive analysis of the database please refer to the McGuiness et al. (2013) publication [22]
dData were only collected for 9 months during 2006 (April to December)
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Results
Sample
The total number of patients in the PCSA population,
along with the projected numbers of patients with cough
illness, the total number of medically attended pertussis
(ICD-9) cases, and laboratory tests are reported in
Table 1.
Laboratory diagnosis of pertussis
The number of laboratory tests performed increased
over the years (Table 1). During the study period,
8398 laboratory tests were positive for B. pertussis
among individuals aged 50–64 years corresponding to
37 % of the total tests performed, and 4029 among
those aged ≥65 years corresponding to 33 % of total
tests performed. Only 45 % of the patients with a
positive laboratory test had a pertussis related diagno-
sis between 14 days prior and 14 days after the index
date. There was no clear time trend in the number of
positive tests for people 50–64 while for those over
65 years the percentage of positive tests increased over
time.
Pertussis incidence by ICD-9 codes
Between April 2006 and December 2010, 8763 pertussis
cases were diagnosed in outpatient settings (ICD9: 033.0,
033.9 and 484.3) among people aged 50–64 and 6369
among people 65 and older (Table 1). The incidence was
estimated to vary between 2.1 and 4.6 cases per 100,000
people across the two age groups (50–64 and ≥65;
Table 1) [18]. Pertussis infections rose particularly in
2010; the diagnosed incidence was 4.6 and 4.4 per
100,000 among people aged 50–64 and ≥65 respectively.
Incidence of cough illness
Nearly 21,000,000 and 27,500,000 cases of cough illness
were reported among people aged 50–64 and ≥65 years,
respectively during the study period (Table 1). Cough ill-
ness reporting varied seasonally, ranging from 780 to
2000 per 100,000 depending on the time of the year
(Fig. 1a and b), with comparable rates across the years.
A
B
Fig. 1 Observed and predicted cough illness by age groups (a-50-64; b ≥65)
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Incidence of cough illness attributable to B. pertussis
The majority of cough illness was unattributed by the
model (Fig. 1a and b). The multiple linear regression
model attributed 519,078 and 465,337 cases of cough ill-
ness to B. pertussis infections among people aged 50–64
and ≥65 years, respectively, accounting for 2.5 and 1.7 %
of all cough illness, respectively. No clear seasonal vari-
ation can be detected (Fig. 2a and b). The annual
incidence of cough illness attributed to B. pertussis in-
creased over the years with a sharp increase in 2009 and
2010 in particular for the older age group (Fig. 2b). Inci-
dence rates in 2006 were 126 and 138 per 100,000 for
people aged 50–64 and ≥65 respectively; by 2008 they
increased to 200 and 203 respectively, to reach the value
of 292 and 464 in 2010.
Depending on the year, these estimated pertussis inci-
dences were 42 to 105 times higher than the ones
reported previously obtained by using only private prac-
titioners diagnosed pertussis/whooping cough case
(ICD9 033.0, 033.9 and 484.3) (Table 1).
Discussion
To the best of our knowledge, this study is the first at-
tempt to quantify the incidence of cough illness attrib-
uted to B. pertussis via regression modeling among
mature adults in the US. The results of our analysis
show that while cough is a seasonal disease (Fig. 1a and
b) with peaks during the winter period, no clear seasonal
trend was observed for estimated pertussis (Fig. 2a). The
model attributed approximately 2 % of cough illness to
pertussis, with the remaining episodes of cough illness
caused by other health conditions. The literature shows
that for adolescents and adults B. pertussis rates among
people with prolonged cough varied from 1 to 17 % [27]
A
B
Fig. 2 Incidence* of cough illness attributed to B. pertussis by month (a) and by year (b). *Please note that as data were only collected for 9 months
during 2006 in the current study, an annual figure was approximated by multiplying by 12/9
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when a stringent definition of positive laboratory test is
used (antibody response to PT). Ward estimated that B.
pertussis accounted for 0.7 to 5.7 episodes of cough ill-
ness, depending of the duration of cough [28]. Specific-
ally among individuals aged ≥65 reported, between 25
and 50 % of pertussis cases had preceding cough diagno-
sis [29]. The lower rate of B. pertussis among cough ill-
ness episodes estimated here can be the results of the
inclusion of acute bronchitis and of the inability of dif-
ferentiating prolonged cough.
The data presented here show that the number of
pertussis cases increased from 8764 diagnosed cases
(ICD-9: 033.0, 033.9, 484.3) during the study period to
approximately 520,000 estimated cases for people aged
50–64 years, and from 6369 to approximately 465,000
for those ≥65. Depending on the year and the age group,
incidence rates were 42 to 105 times higher than the
ones calculated using only medically diagnosed pertussis
cases [18]. In 2010, the estimated incidence was 94 and
264 times higher than national reported incidences
(NNDSS) for individuals aged 40–65 and ≥65 years,
respectively [30]. Moreover, incidence rates for cough
illness attributable to pertussis increased each year, with
more than a two folds increase among people ≥65.
Our results are in line with previous US studies on per-
tussis performed during the mid-to-late 1990s reporting
annual rates varying from 176 to 1500/100,000 [28, 31,
32]. The Nanning et al. study, which enrolled 307 adults
(≥18 years) into a single-center prospective study [31]
estimated a pertussis incidence of 176/100,000 person-
years during 1997–2000. The Strebel et al. prospective
study enrolled 212 patients aged 10–49 years old with
acute paroxysmal cough or cough illness for 7–34 days in
Minnesota [32]. On the basis of any positive laboratory re-
sult, the estimated annual incidence of pertussis was 507/
100,000 person-years. A multicenter prospective study of
2781 healthy subjects, of which 1391 received acellular
pertussis vaccine, aged 15–65 years enrolled in a random-
ized, double-blind trial of an acellular pertussis vaccine
reported an annual pertussis incidence of 370–450 cases/
100,000 [28]. Hodder et al., specifically analyzed rates of B
pertussis among individuals aged 65 and older [29]. De-
pending on the definition of infection, incidence varied
from 19.7 to 3.3 per 100 person-years.
These variations in B. pertussis incidence estimations
are associated with the specific populations studied as
well as the pertussis definitions used.
The results of our study, along with the results of previ-
ous US studies, support the claim that pertussis is widely
underreported, especially among adults, in whom clinical
presentation varies widely [7, 11] . Pertussis is under rec-
ognized as a cause of cough, clinical suspicion may be
low, and the disease may be mild enough that medical
care is not sought. Direct assessment of pertussis disease
incidence is not possible because not all cases of pertussis
are diagnosed or laboratory confirmed, partly due to la-
boratory testing being uncommon outside of outbreaks. A
call for broader laboratory testing among elderly adults
may be considered given the results of this study. Some
tests are most sensitive in the early stages of the disease
[13, 33], before the adult patient seeks medical attention.
Testing at the later stages of the disease results in a higher
false negative rate [13, 33] and an underestimation of dis-
ease incidence. Improvements in laboratory diagnosis may
be associated with a rise in the number of pertussis re-
ported cases. Nevertheless, care must be taken because B.
holmesii and B. pertussis genomes share the same IS481in-
sertion sequence and routine polymerase chain reaction
(PCR) techniques can falsely attribute respiratory infection
due to B. holmesii to B. pertussis, ie false positives [34].
Other possible explanations for the rising pertussis inci-
dence are: greater awareness of pertussis; the use of acellu-
lar versus whole-cell vaccines; genetic changes in B.
pertussis; and waning of vaccine-induced immunity [4,
27]. The number of outbreaks of pertussis has increased
in the last years [35–38], with obvious health and eco-
nomic consequences.
The data presented here suggest that B. pertussis infec-
tion is common in mature adults and particularly among
the people aged ≥65. According to the literature, infec-
tions in adults are endemic and not cyclical as in chil-
dren [27]. Vaccination among children and young adults
may have shifted the incidence of pertussis to older
adults [39]. Because not all adults who get pertussis will
experience a severe cough, adults often unknowingly
spread pertussis to infants, who are at risk for a severe,
sometimes life-threatening illness. These results support
the ACIP decision to extend Tdap vaccination to indi-
viduals aged 65 and older [10].
Strengths and limitations
Strengths of the study include the large sample size and
the geographical representativeness of the sample. How-
ever, the results of this study should be interpreted in
the context of its limitations. Claims data are inherently
limiting, because they are collected for billing and reim-
bursement purposes rather than for research. Further-
more, data entry errors at the site of care cannot be
corrected.
Only patients seeking medical attention from private
practitioners were included. Patients visiting emergency
departments and/or hospitals as well as those who do
not seek medical attention are not included in our esti-
mates. Moreover, we included only individuals with a
whooping cough diagnosis or a pertussis like diagnosis
defined as wither cough illness (length of cough illness
was not taken into consideration) or acute bronchitis.
Therefore, given the conservative definition of pertussis
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like diagnosis our data likely underestimate the true inci-
dence of pertussis. However, we did include cases of
whooping cough due to unspecified organisms, some of
which may not have been due to B. pertussis, which
probably led to a small overestimation in this regard.
We did not test whether the results of the analysis may
change with a more restrictive definition of pertussis or
cough illness.
Measurement error within the current study is also
likely. By including only positive B. pertussis laboratory
tests we may have underestimated the real incidence of
pertussis. The retrospective, observational nature of the
study should also be considered when interpreting the
results. Retrospective analyses demonstrate associations
but do not indicate causality and could make the results
subject to selection bias.
Lastly, the incidence of cough attributed to B. pertussis
was based on mathematical modeling. Models try to
mimic the reality and are subject to numerous limita-
tions and assumptions. Although we used methodology
from the published literature [15, 17, 22, 23], there may
be more efficient way of estimated the overall incidence
of pertussis.
Conclusions
Overall, our findings indicate that B. pertussis incidence
is substantial in adults aged ≥50 years that considerably
exceeds the generally reported disease incidence. Al-
though only approximately 2 % of cough illness was at-
tributed to B. pertussis, the gross disease burden
associated with pertussis is sizeable from a public health
perspective. These results highlight the importance of
improving clinical awareness of pertussis in adults, as
well as the need for better prevention and control of
pertussis in adults. Incidence rates of cough illness at-
tributed to B. pertussis increased from 2006 to 2010.
Further research is needed to better understand the inci-
dence of disease among people over 50 and to validate
these findings.
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